Navigation Links
MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Date:9/24/2007

GAITHERSBURG, Md., Sept. 24 /PRNewswire/ -- MedImmune, Inc. announced today that it has licensed its proprietary reverse genetics intellectual property to GlaxoSmithKline to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome.

"MedImmune is pleased to enter into a fourth agreement to license our reverse genetics technology to manufacturers," said Jonathan Klein-Evans, J.D., MedImmune's vice president, intellectual property. "Making this important technology available to the vaccine development team at GlaxoSmithKline and their peers at other companies may have a significant positive impact on the manufacturing of influenza vaccines due to the efficiency and reliability of the process."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune remains committed to making sure that the technology is accessible to government institutions and industry manufacturers. As such, the company has offered other influenza vaccine manufacturers non-exclusive licenses to this intellectual property estate for use in manufacturing seasonal or pandemic vaccines.

Since December of 2006, MedImmune has licensed its reverse genetics technology to CSL Limited of Australia, sanofi pasteur and Novartis.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L) (NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Vitamin C reverses pre eclampsia
9. Creams may not reverse aging
10. Researchers reversed the process of memory loss
11. Faster way of producing Bird flu vaccine using Reverse Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... 2017 , ... The JPR Group, a public relations and ... will be assisting HackensackUMC Mountainside with its public relations efforts, effective January 2017. ... towns. The firm will be working closely with HackensackUMC Mountainside’s internal marketing operations. ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products ... The Emoji Scale is now available on Apple as a fun, free emoji sticker ... by choosing one of the ten color coded values on The Emoji Scale. ...
(Date:1/13/2017)... Madrid, Spain (PRWEB) , ... January 13, 2017 , ... ... the Melia Avenida America hotel on March 3-4, 2017. This Congress is expertly ... focused on the management of patients with lung cancer. , Chaired by Dr. Giorgio ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... has taken on the challenge of providing additional organic alternatives for customers who ... launch of the brand’s new line of all-natural activated charcoal products, Moody Zook ...
(Date:1/13/2017)... ... , ... People who have sensitive teeth are about as common as those ... Sadly, most dental hygiene products in the market contain chemical ingredients that only aggravate ... their daily oral care routine to keep their teeth white and healthy is a ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , January 16, 2017 Bill is ... number of general management and leadership positions with global medical device ... a strong track record of launching new products and building successful ... , Africa and North ... ...
(Date:1/16/2017)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce ... to its Board of Directors. He is the President ... LLC . He is also the Chief Investment Officer ... firm with over $1.5 billion under management. ... analysis and portfolio management. He began his career in ...
(Date:1/15/2017)... , Jan. 14, 2017 ImmersiveTouch Inc., ... for surgeons, today announced recent appointments strengthening their Executive ... James Bowman as Chief Executive Officer, Jay ... as Vice President of Sales and Jia ... Mr. Bowman has 20 ...
Breaking Medicine Technology: